Since the advent of hybridoma technology, murine monoclonal antibodies with therapeutic potential have been widely applied in clinical settings, aiding the diagnosis and treatment of various diseases. However, animal-derived antibodies often carry immunogenicity, causing rapid clearance from human circulation and systemic inflammatory responses during disease treatment—limiting their therapeutic efficacy. While recombinant antibodies (e.g., scFv) have entered clinical use in recent years, they still exhibit certain immunogenicity.

Antibody Humanization technology overcomes this limitation, effectively reducing immunogenicity in monoclonal and recombinant antibodies (including scFv), thereby enhancing drug potency and treatment outcomes.

KMD Bioscience provides high-quality Antibody Humanization services backed by extensive experience and multiple successful projects. Our platform humanizes antibodies from diverse species, including non-human primates, rabbits, dogs, chickens, and sheep, to reduce immunogenicity.We employ three advanced humanization strategies: 

(1) Phage Display-based CDR Grafting.

(2) Phage Display-based Chain Shuffling.

(3) Mammalian Cell Surface Display-based FACS Screening of Humanized IgG Libraries.

These approaches generate scFv antibodies that retain target specificity and affinity while significantly or fully eliminating human immunogenicity. Optimized scFv antibodies exhibit extremely low immunogenicity, comparable to mature human antibodies, without compromising affinity or specificity. Post-affinity maturation, scFv affinity increases by ≥ 8-fold. To validate scFv efficacy, we conduct comprehensive characterization via ELISA, Western Blot (WB), IC50, SPR, and Endotoxin Testing.